Company Overview and News
KUALA LUMPUR: Luxchem Corp Bhd , Lotte Chemical Titan Holding Bhd, Yinson Holdings Bhd , Censof Holdings Bhd and Bintulu Port Holdings Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
It’s a deal: Johari (second from right) and OBYU Holdings Sdn Bhd founder and advisor Tan Sri Bustari Yusof witnessing the exchange of documents between Ahmadi (left) and Hadzari.
KUCHING: Bintulu Port Holdings Bhd (BPHB) plans to diversify into providing bunkering services at Bintulu Port for commercial vessels. The company has the Samalaju Industrial Port on the South China sea.
Entulu has represented Selangau since 2004. — Foto ehsan Facebook/Joseph Entulu BelaunKUCHING, March 30 ― Parti Rakyat Sarawak (PRS) deputy president Datuk Joseph Entulu Belaun will not be fielded to defend his Selangau parliamentary seat in the upcoming general election, party president Tan Sri Dr James Masing said today.
A healthy cash position is an important indicator to evaluate whether a company’s financials are sound to withstand any unforeseen shocks.
The multipurpose Samalaju Industrial Port is the shipping hub for heavy industries in the Sarawak Corridor of Renewable Energy
Ali said not all countries consider their security forces, education and health workers as civil servants like Malaysia. — Picture by Yusof Mat IsaKUCHING, April 21 ― Malaysia's public work force of 1.6 million is the appropriate size for the country, Chief Secretary to the Government Tan Sri Dr Ali Hamsa said today.
KUCHING: Bintulu Port Holdings Bhd (BPHB) has secured contracts from major oil and gas (O&G) companies as the company expands its port business to provide base support services for the O&G industry.
KUALA LUMPUR (Dec 29): The FBM KLCI reversed its earlier losses at the midday break and edged up 0.2% on some mild window-dressing activities.
KUALA LUMPUR (Dec 29): The FBM KLCI remained in negative zone as index-linked banking stocks weighed on the benchmark index in line with the retreat at regional markets.
KUALA LUMPUR (Nov 30): The FBM KLCI remained in negative territory as selling persisted amidst tepid investor sentiment, despite the uptrend at regional markets.
KUALA LUMPUR (Nov 30): The FBM KLCI sunk into the negative zone at mid-morning as decliners overtook advancers, and the local market sentiment stayed wary with lack of fresh catalysts.
KUALA LUMPUR (Nov 29): The FBM KLCI dipped at the midday break today, as sentiment at the local market soured in line with regional bourses.
Energy Brent Crude was up 1.22% to US$47.43 per barrel at 5:02pm. Forex Ringgit down 0.03% to 4.4198 versus the US dollar at 4.32pm. Top foreign stories Symantec to acquire LifeLock for US$2.3b: Symantec Corp said it would acquire US identity theft protection services company LifeLock Inc for US$2.3 billion, in a deal that it hopes will prop up sales at its Norton cybersecurity unit. - Reuters Citi and JPMorgan top list of globally systemic banks: Citi joined JPMorgan as the world's most systemically important banks, replacing HSBC in a group of 30 lenders who must hold extra capital from 2019 to preserve financial stability.
KUALA LUMPUR (Oct 25): The FBM KLCI remained in negative territory at the midday break today, weighed by telecommunication stocks and select blue chips.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...